<?xml version="1.0" ?>
<document id="03bb746ba6fb4c250b5f8f9ff0e5013b2c49b8f7">
  <chunk id="03bb746ba6fb4c250b5f8f9ff0e5013b2c49b8f7.c0" text="Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates">
    <entity charOffset="54-63" id="03bb746ba6fb4c250b5f8f9ff0e5013b2c49b8f7.c0.e0" ontology_id="DOID_2237" text="hepatitis" type="disease"/>
    <entity charOffset="54-65" id="03bb746ba6fb4c250b5f8f9ff0e5013b2c49b8f7.c0.e1" ontology_id="DOID_2043" text="hepatitis B" type="disease"/>
  </chunk>
  <chunk id="03bb746ba6fb4c250b5f8f9ff0e5013b2c49b8f7.c1" text="Background: A new promising therapeutic approach has emerged for patients chronically infected by the hepatitis B virus (HBV) with the development of a non-replicative adenovirus vector vaccine candidate (Ad-HBV). The vaccine encodes a fusion protein composed of a truncated HBV core protein, mutated polymerase protein, and two envelope domains. In this study, we assessed the immunogenicity of Ad-HBV administered to cynomolgus monkeys during a non-clinical safety assessment. Methods: The virus was subcutaneously administered at 1.0 × 10 9 viral particles (VP)/animal (low-dose group), 1.0 × 10 10 VP/animal (mid-dose group), and 1.0 × 10 11 VP/animal (high-dose group); the control groups were administered an Ad5-null virus (1.0 × 10 11 VP/animal) and saline only.">
    <entity charOffset="102-111" id="03bb746ba6fb4c250b5f8f9ff0e5013b2c49b8f7.c1.e0" ontology_id="DOID_2237" text="hepatitis" type="disease"/>
    <entity charOffset="102-113" id="03bb746ba6fb4c250b5f8f9ff0e5013b2c49b8f7.c1.e1" ontology_id="DOID_2043" text="hepatitis B" type="disease"/>
    <entity charOffset="243-250" id="03bb746ba6fb4c250b5f8f9ff0e5013b2c49b8f7.c1.e2" ontology_id="CHEBI_16541" text="protein" type="chemical"/>
    <entity charOffset="284-291" id="03bb746ba6fb4c250b5f8f9ff0e5013b2c49b8f7.c1.e3" ontology_id="CHEBI_16541" text="protein" type="chemical"/>
    <entity charOffset="312-319" id="03bb746ba6fb4c250b5f8f9ff0e5013b2c49b8f7.c1.e4" ontology_id="CHEBI_16541" text="protein" type="chemical"/>
    <pair e1="03bb746ba6fb4c250b5f8f9ff0e5013b2c49b8f7.c1.e0" e2="03bb746ba6fb4c250b5f8f9ff0e5013b2c49b8f7.c1.e2" id="03bb746ba6fb4c250b5f8f9ff0e5013b2c49b8f7.c1.p0" relation="true"/>
    <pair e1="03bb746ba6fb4c250b5f8f9ff0e5013b2c49b8f7.c1.e0" e2="03bb746ba6fb4c250b5f8f9ff0e5013b2c49b8f7.c1.e3" id="03bb746ba6fb4c250b5f8f9ff0e5013b2c49b8f7.c1.p1" relation="true"/>
    <pair e1="03bb746ba6fb4c250b5f8f9ff0e5013b2c49b8f7.c1.e0" e2="03bb746ba6fb4c250b5f8f9ff0e5013b2c49b8f7.c1.e4" id="03bb746ba6fb4c250b5f8f9ff0e5013b2c49b8f7.c1.p2" relation="true"/>
    <pair e1="03bb746ba6fb4c250b5f8f9ff0e5013b2c49b8f7.c1.e1" e2="03bb746ba6fb4c250b5f8f9ff0e5013b2c49b8f7.c1.e2" id="03bb746ba6fb4c250b5f8f9ff0e5013b2c49b8f7.c1.p3" relation="true"/>
    <pair e1="03bb746ba6fb4c250b5f8f9ff0e5013b2c49b8f7.c1.e1" e2="03bb746ba6fb4c250b5f8f9ff0e5013b2c49b8f7.c1.e3" id="03bb746ba6fb4c250b5f8f9ff0e5013b2c49b8f7.c1.p4" relation="true"/>
    <pair e1="03bb746ba6fb4c250b5f8f9ff0e5013b2c49b8f7.c1.e1" e2="03bb746ba6fb4c250b5f8f9ff0e5013b2c49b8f7.c1.e4" id="03bb746ba6fb4c250b5f8f9ff0e5013b2c49b8f7.c1.p5" relation="true"/>
  </chunk>
  <chunk id="03bb746ba6fb4c250b5f8f9ff0e5013b2c49b8f7.c2" text="Results: Except for inflammatory cell infiltration under the skin at the injection sites and transient elevation of body temperature and serum albumin, no Ad-HBV-related toxic effects were noted in any treatment group. Moreover, interferon (IFN)-γ enzyme-linked immunospot assays showed that Ad-HBV induced the targeting of T cells to a broad spectrum of HBV-specific epitopes spanning all three of the selected HBV immunogens (core, polymerase, and envelope domains) in a dose-dependent manner. Although anti-Ad antibody was produced in all groups (except for the saline control), the antibody titers were significantly lower in the high-dose Ad-HBV group than in the group that received the same dose of the Ad-null empty vector. In addition, the IFN-γ and IL-2 expression levels in the liver were significantly improved for the mid-dose, high-dose, and Ad-null control group (p &lt; 0.05), but not for the low-dose group.">
    <entity charOffset="229-239" id="03bb746ba6fb4c250b5f8f9ff0e5013b2c49b8f7.c2.e0" ontology_id="CHEBI_52999" text="interferon" type="chemical"/>
  </chunk>
  <chunk id="03bb746ba6fb4c250b5f8f9ff0e5013b2c49b8f7.c3" text="Conclusions: Taken together, this safety assessment indicates that the Ad-HBV candidate vaccine is a potent specific immunotherapeutic agent, supporting its further clinical development as an anti-HBV infection vaccine."/>
</document>
